BridgeBio Pharma Inc. (BBIO) Misses Q2 EPS by 18c

BridgeBio Pharma Inc. (NASDAQ: BBIO) reported Q2 EPS of ($0.78), $0.18 worse than the analyst estimate of ($0.60). Revenue for the quarter came in at $243.67 million versus the consensus estimate of $220.19 million.

For earnings history and earnings-related data on BridgeBio Pharma Inc. (BBIO) click here.

You May Also Be Interested In

• S&P Dow Jones Indices adds Bloom Energy to S&P 500 index
• S&P announces major changes in S&P 100, S&P 500, S&P 400
• Huntington Ingalls wins $336 million Navy contract for CVN 82